CRISPR Therapeutics AGCRSPNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank27
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P27
Within normal range
vs 2Y Ago
-2.8x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-139.11%
202446.39%
202349.37%
2022-216.55%
2021278.12%
2020-613.52%
2019150.49%
2018-27.08%
2017-33.58%
2016-200.09%